Home › Compare › KVLQF vs ABBV
KVLQF yields 2857.14% · ABBV yields 3.06%● Live data
📍 KVLQF pulled ahead of the other in Year 1
Combined, KVLQF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KVLQF + ABBV for your $10,000?
ValOre Metals Corp., an exploration stage company, engages in the acquisition, exploration, evaluation, and development of mineral resource properties in Canada and Brazil. The company explores for uranium, palladium, platinum, and gold deposits. It holds 100% interests in the Angilak Property that covers an area of 29,595.57 hectares and the Baffin Gold Property that covers an area of 352,727.87 hectares located in Nunavut Territory; the Hatchet Lake Property that consists of 6 claims covering an area of 13,711 hectares located in Saskatchewan; and the Pedra Branca Project that includes 38 exploration licenses covering an area of 38,940 hectares located in north-eastern Brazil. The company was formerly known as Kivalliq Energy Corporation and changed its name to ValOre Metals Corp. in June 2018. ValOre Metals Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Full KVLQF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.